Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus

By Gallwitz Baptist  

Treatments in Endocrinology, Vol. 4, Iss. 6, 2005-01 ,pp. : 361-370

Adis International

Access to resources Recommend Favorite

Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists

By  

Current Diabetes Reviews, Vol. 5, Iss. 4, 2009-11 ,pp. : 266-275

Bentham Science Publishers

Access to resources Recommend Favorite

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome

By  

Current Vascular Pharmacology, Vol. 15, Iss. 3, 2017-04 ,pp. : 218-229

Bentham Science Publishers

Access to resources Recommend Favorite

Potentiation and prolongation of the insulinotropic action of glucagon-like peptide 1 by methyl pyruvate or dimethyl ester of l-glutamic acid in a type 2 diabetes animal model

By Cancelas Jesús   Villanueva-Peñacrrillo María   Valverde Isabel   Malaisse Willy  

Endocrine Journal, Vol. 16, Iss. 2, 2001-11 ,pp. : 113-116

Humana Press, Inc

Access to resources Recommend Favorite

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus

By Hogan Andrew   Gaoatswe Gadintshware   Lynch Lydia   Corrigan Michelle   Woods Conor   O’Connell Jean   O’Shea Donal  

Diabetologia, Vol. 57, Iss. 4, 2014-04 ,pp. : 781-784

Springer Publishing Company

Access to resources Recommend Favorite